Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: gefitinib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00039390

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 29

Registration Number: NCT00049335

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 87 locations

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Liver Metastases
Stage IV Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: floxuridine
Drug: dexamethasone
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00026234

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: capecitabine
Drug: gemcitabine hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 60

Registration Number: NCT00042965

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 47 locations

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Phase 2

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer

Interventions: Drug: capecitabine
Drug: gemcitabine hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2017-09-12

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 57

Registration Number: NCT00033540

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
North Bay Cancer Center, Fairfield, California, United States

and more 109 locations

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-04-05

Lead Sponsor: NYU Langone Health

Registration Number: NCT00010023

Locations: 🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States

Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Standard Treatment
Drug: capecitabine

First Posted Date: 2003-01-27

Last Posted Date: 2016-08-12

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 633

Registration Number: NCT00024102

Locations: 🇨🇦
Mount Sinai Hospital - Toronto, Toronto, Ontario, Canada
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

and more 326 locations

Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: capecitabine
Drug: oxaliplatin

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 48

Registration Number: NCT00040859

Locations: 🇺🇸
Mercy Medical Center - Sioux City, Sioux City, Iowa, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

and more 3 locations